Pembrolizumab plus nab-paclitaxel and platinum as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma: a prospective phase Ⅱstudy

Conclusion: Pembrolizumab combined with nab-paclitaxel and platinum shows encouraging antitumor activity accompanied with a manageable safety profile in untreated R/M HNSCC patients in China.PMID:38599639 | DOI:10.3760/cma.j.cn115330-20231013-00143

Source: Cancer Control - April 10, 2024 Category: Cancer & Oncology Authors: X R Chen Z C Xie H Z Lu J L Yang L Gui Source Type: research